Published • loading... • Updated
The Road to Diagnosis: Cindy’s Journey With Non-Cystic Fibrosis Bronchiectasis
Persistent respiratory symptoms and repeated testing led specialists to diagnose non-cystic fibrosis bronchiectasis after years of treatment attempts.
- Former educator Cindy received a bronchiectasis diagnosis in 2021 after ruling out COPD, then began treatment with BRINSUPRI in November 2025, the first FDA-approved medication for the chronic lung condition.
- Bronchiectasis is a chronic, irreversible lung disease often misidentified as asthma or COPD. An estimated 500,000 adults in the United States currently face the diagnosis, experiencing chronic cough, excess mucus, and recurrent infections.
- Cindy, now more than 10 months into treatment, stated: "With BRINSUPRI and a correct diagnosis, I can laser focus on managing my bronchiectasis." She reports the medication has made a significant difference in her daily life.
- Patients taking BRINSUPRI for non-cystic fibrosis bronchiectasis should monitor for side effects including upper respiratory tract infections, rash, and high blood pressure. Healthcare providers advise reporting new skin or dental symptoms immediately.
- BRINSUPRI remains the only FDA-approved option for adults and children 12 years and older with the condition. While bronchiectasis is chronic, management plans and medical support enable patients like Cindy to maintain active lifestyles.
Insights by Ground AI
54 Articles
54 Articles
Bedford Gazette+53 Reposted by 53 other sources
The Road to Diagnosis: Cindy’s Journey With Non-Cystic Fibrosis Bronchiectasis
(StatePoint) Cindy has always been active. As a physical education teacher, and later an elementary school principal, she built her career around helping others lead healthy, fulfilling lives. But behind that active lifestyle, she was on a decades-long search for…
Coverage Details
Total News Sources54
Leaning Left11Leaning Right3Center34Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 23%
C 71%
Factuality
To view factuality data please Upgrade to Premium
